Cadila Healthcare today announced the launch of NuPatch - India's first indigenously manufactured Diclofenac transdermal patch for pain relief.According to a release issued by Cadila to the BSE today, NuPatch is manufactured at the group's dedicated transdermal facility at Moraiya in Ahmedabad."NuPatch's novel drug delivery system through the transdermal delivery route offers several advantages. It addresses two significant problems posed by the traditional oral dosage form - local gastric irritation and the need to consume two to three doses in a day. NuPatch contains 100 mg of Diclofenac, a popular painkiller. Instead of the thrice daily dosage as in the case of the oral dosage form, NuPatch needs to be applied just once daily and provides extended pair relief for 24 hours at a stretch," the release said.
